View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Nov. 04, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Trading Symbol	TRXC
Entity Registrant Name	TRANSENTERIX INC.
Entity Central Index Key	0000876378
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		115,058,244

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Revenue	$ 1,466		$ 1,466
Cost of revenue	1,031		1,031
Gross profit	435		435
Operating Expenses
Research and development	7,011	$ 7,048	21,760	$ 21,111
Sales and marketing	2,574	413	5,563	1,161
General and administrative	2,793	1,762	7,927	5,607
Amortization of intangible assets	1,709	338	5,312	589
Change in fair value of contingent consideration	(100)		1,700
Inventory write-down related to restructuring			2,565
Restructuring and other charges			3,085
Goodwill impairment			61,784
Acquisition related costs		4,003		4,003
Total Operating Expenses	13,987	13,564	109,696	32,471
Operating Loss	(13,552)	(13,564)	(109,261)	(32,471)
Other Expense
Interest expense, net	(432)	(436)	(1,499)	(997)
Other (expense) income	(30)		65
Total Other Expense, net	(462)	(436)	(1,434)	(997)
Loss before income taxes	(14,014)	(14,000)	(110,695)	(33,468)
Income tax benefit	1,070	99	4,707	99
Net loss	(12,944)	(13,901)	(105,988)	(33,369)
Other comprehensive gain (loss)
Foreign currency translation gain (loss)	689	(429)	2,199	(429)
Comprehensive loss	$ (12,255)	$ (14,330)	$ (103,789)	$ (33,798)
Net loss per share - basic and diluted	$ (0.11)	$ (0.16)	$ (0.95)	$ (0.46)
Weighted average common shares outstanding - basic and diluted	114,946	86,044	111,189	72,713

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current Assets
Cash and cash equivalents	$ 42,518	$ 38,449
Accounts receivable, net	616	76
Inventories	2,250	3,923
Interest receivable	15	6
Other current assets	8,149	6,689
Total Current Assets	53,548	49,143
Restricted cash	10,353
Accounts receivable, net of current portion	274
Inventories, net of current portion		709
Property and equipment, net	4,614	4,408
Intellectual property, net	41,260	46,898
In-process research and development	16,972	16,511
Goodwill	69,948	130,869
Other long term assets	63	64
Total Assets	197,032	248,602
Current Liabilities
Accounts payable	2,596	4,450
Accrued expenses	7,246	7,395
Contingent consideration – current portion	11,325	12,500
Notes payable - current portion	7,826	6,727
Total Current Liabilities	28,993	31,072
Long Term Liabilities
Contingent consideration – less current portion	13,875	11,000
Net deferred tax liabilities	11,971	16,263
Notes payable - less current portion, net of debt discount	7,059	12,990
Total Liabilities	61,898	71,325
Commitments and Contingencies
Stockholders’ Equity
Common stock $0.001 par value, 750,000,000 shares authorized at September 30, 2016 and December 31, 2015; 115,086,256 and 100,180,872 shares issued at September 30, 2016 and December 31, 2015, respectively; and 115,014,711 and 100,149,453 shares outstanding at September 30, 2016 and December 31, 2015, respectively	115	100
Additional paid-in capital	425,041	363,280
Accumulated deficit	(288,852)	(182,864)
Treasury stock at cost, 71,545 and 31,419 shares at September 30, 2016 and December 31, 2015, respectively	(203)	(73)
Accumulated other comprehensive loss	(967)	(3,166)
Total Stockholders’ Equity	135,134	177,277
Total Liabilities and Stockholders’ Equity	$ 197,032	$ 248,602

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Statement Of Partners Capital [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	115,086,256	100,180,872
Common stock, shares outstanding	115,014,711	100,149,453
Treasury stock, shares	71,545	31,419

Consolidated Statements of Shareholders' Equity (Unaudited) - 9 months ended Sep. 30, 2016 - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Balance at Dec. 31, 2015	$ 177,277	$ 100	$ (73)	$ 363,280	$ (182,864)	$ (3,166)
Balance, Shares at Dec. 31, 2015		100,180	(31)
Stock-based compensation	3,858			3,858
Issuance of common stock, net of issuance costs	57,637	$ 15		57,622
Issuance of common stock, net of issuance costs, Shares		14,474
Exercise of stock options and restricted stock units	165			165
Exercise of stock options and restricted stock units, Shares		351
Return of common stock to pay withholding taxes on restricted stock	(130)		$ (130)
Return of common stock to pay withholding taxes on restricted stock, Shares			(41)
Issuance of common stock for services	116			116
Issuance of common stock for services, Shares		81
Other comprehensive gain	2,199					2,199
Net loss	(105,988)				(105,988)
Balance at Sep. 30, 2016	$ 135,134	$ 115	$ (203)	$ 425,041	$ (288,852)	$ (967)
Balance, Shares at Sep. 30, 2016		115,086	(72)

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating Activities
Net loss	$ (105,988)	$ (33,369)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
Depreciation	1,498	802
Amortization of intangible assets	5,312	589
Amortization of debt discount and debt issuance costs	140	89
Stock-based compensation	3,858	2,388
Common stock issued for services	116
Inventory write-down related to restructuring	2,565
Loss on disposal of property		34
Non-cash restructuring and other charges	2,551
Goodwill impairment	61,784
Deferred tax benefit	(4,725)	(99)
Change in fair value of contingent consideration	1,700
Changes in operating assets and liabilities, net of effect of acquisition:
Accounts receivable	(809)	133
Interest receivable	(9)	(5)
Inventories	(1,883)	(250)
Other current and long term assets	(1,290)	(248)
Accounts payable	(1,917)	984
Accrued expenses	(168)	4,127
Restricted cash	(10,353)	250
Net cash and cash equivalents used in operating activities	(47,618)	(24,575)
Investing Activities
Payment for acquisition		(25,000)
Purchase of property and equipment	(878)	(728)
Net cash and cash equivalents used in investing activities	(878)	(25,728)
Financing Activities
Payment of debt	(4,972)
Proceeds from issuance of common stock, net of issuance costs	57,637	58,295
Proceeds from issuance of debt, net of debt discount		9,886
Taxes paid related to net share settlement of vesting of restricted stock units	(130)	(3)
Proceeds from exercise of stock options and warrants	163	252
Net cash and cash equivalents provided by financing activities	52,698	68,430
Effect of exchange rate changes on cash and cash equivalents	(133)
Net increase in cash and cash equivalents	4,069	18,127
Cash and cash equivalents, beginning of period	38,449	34,766
Cash and cash equivalents, end of period	42,518	52,893
Supplemental Disclosure for Cash Flow Information
Interest paid	1,019	598
Supplemental Schedule of Noncash Investing Activities
Transfer of inventory to property and equipment	$ 1,866
Issuance of common stock warrants		96
Contingent consideration related to acquisition		24,300
Issuance of common stock related to acquisition		$ 43,677

Organization and Capitalization	9 Months Ended
Organization and Capitalization	Sep. 30, 2016
Accounting Policies [Abstract]
Organization and Capitalization	1. Organization and Capitalization TransEnterix, Inc. (the “Company”) is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical challenges associated with current laparoscopic and robotic options. The Company is focused on the commercialization and further development of its Senhance™ Surgical Robotic System (formerly known as the ALF-X ® Surgical Robotic System) (the “Senhance System”), a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology. The Company also developed the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance System has been granted a CE Mark in Europe for laparoscopic abdominal and pelvic surgery, as well as limited thoracic operations excluding cardiac and vascular surgery, but is not available for sale in the U.S. The SurgiBot System is not available for sale in any market. The Senhance System is a multi-port robotic surgery system which allows multiple arms to control robotic instruments and a camera. The system features advanced technology to enable surgeons with haptic feedback and the ability to move the camera via eye movement. The system replicates laparoscopic motion that is familiar to experienced surgeons, and features three-dimensional high definition (“3DHD”) vision technology. The Senhance System also offers responsible economics to hospitals by offering robotic technology with reusable instruments with minimal additional costs per surgery. The SurgiBot System is designed to utilize flexible instruments through articulating channels controlled directly by the surgeon, with robotic assistance, while the surgeon remains patient-side within the sterile field. In June 2015, the Company submitted a 510(k) application to the FDA for the SurgiBot System. On April 19, 2016, the FDA notified the Company that the SurgiBot System did not meet the criteria for substantial equivalence based on the data and information submitted by TransEnterix in the 510(k) submission. As a result, the Company has reprioritized its near-term regulatory efforts to focus on the 510(k) submission for the Senhance System. Consequently, in May 2016, the Company implemented a restructuring plan. See Note 14 to the consolidated financial statements for further details regarding the restructuring. On September 3, 2013, TransEnterix Surgical, Inc. a Delaware corporation (“TransEnterix Surgical”), and SafeStitch Medical, Inc., a Delaware corporation (“SafeStitch”) consummated a merger transaction whereby TransEnterix Surgical merged with a merger subsidiary of SafeStitch, with TransEnterix Surgical as the surviving entity in the merger (the “Merger”). As a result of the Merger, TransEnterix Surgical became a wholly owned subsidiary of SafeStitch. On December 6, 2013, SafeStitch changed its name to TransEnterix, Inc. and increased the authorized shares of common stock from 225,000,000 to 750,000,000, and authorized 25,000,000 shares of preferred stock, par value $0.01 per share. On September 18, 2015, the Company entered into a Membership Interest Purchase Agreement, (the “Purchase Agreement”) with SOFAR S.p.A., (“SOFAR”) as seller, Vulcanos S.r.l. (“Vulcanos”), as the acquired company, and TransEnterix International, Inc. (“TransEnterix International”), a direct, wholly owned subsidiary of the Company which was incorporated in September 2015, as buyer. The closing of the transactions occurred on September 21, 2015 (the “Closing Date”) pursuant to which the Company acquired all of the membership interests of Vulcanos from SOFAR (now known as the “Senhance Acquisition”), and changed the name of Vulcanos to TransEnterix Italia S.r.l (“TransEnterix Italia”). The Senhance Acquisition included all of the assets, employees and contracts related to the Senhance System. See Note 3 for a description of the related transactions. As used herein, the term “Company” refers to the combination of SafeStitch and TransEnterix Surgical after giving effect to the Merger, and includes TransEnterix International, TransEnterix Italia, TransEnterix Europe S.Á.R.L, TransEnterix Europe S.Á.R.L, Bertrange, Swiss Branch, Lugano and TransEnterix Asia PTE. LTD. after giving effect to the Senhance Acquisition, the term “SafeStitch” refers to the historic business of SafeStitch Medical, Inc. prior to the Merger, and the term “TransEnterix Surgical” refers to the historic business of TransEnterix Surgical, Inc. prior to the Merger. The Company operates in one business segment.

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The Company has prepared the accompanying unaudited interim condensed consolidated financial statements in accordance with the instructions to Form 10-Q and the standards of accounting measurement set forth in the Interim Reporting Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). Consequently, the Company has not necessarily included in this Form 10-Q all information and footnotes required for audited financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements in this Form 10-Q contain all adjustments, consisting only of normal recurring adjustments, except as otherwise indicated, necessary for a fair statement of its financial position, results of operations, and cash flows of the Company for all periods presented. The results reported in these condensed consolidated financial statements should not be regarded as necessarily indicative of results that may be expected for any subsequent period or for the entire year. These unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Company’s audited financial statements and the notes thereto included in the Company’s latest Annual Report on Form 10-K. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in the accompanying interim consolidated financial statements. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The accompanying Consolidated Financial Statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries, SafeStitch LLC, TransEnterix Surgical, Inc., TransEnterix International, Inc., TransEnterix Italia S.r.l., TransEnterix Europe S.Á.R.L, TransEnterix Europe S.Á.R.L, Bertrange, Swiss Branch, Lugano and TransEnterix Asia PTE. LTD. All inter-company accounts and transactions have been eliminated in consolidation.

Going Concern

The accompanying consolidated financial statements have been prepared on a going concern basis. The Company has accumulated a deficit of approximately $288.9 million as of September 30, 2016, and has not generated significant revenue or positive cash flows from operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty. To meet its capital needs, the Company is considering multiple alternatives, including, but not limited to, additional equity financings, debt financings and other funding transactions. There can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. If the Company is unable to obtain the necessary capital, it will need to pursue a plan to license or sell its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include identifiable intangible assets and goodwill, stock compensation expense, excess and obsolete inventory reserves, and deferred tax asset valuation allowances.

Cash and Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments with original maturities of 90 days or less at the time of purchase to be cash equivalents and investments with original maturities of between 91 days and one year to be short-term investments. In order to manage exposure to credit risk, the Company invests in high-quality investments rated at least A2 by Moody’s Investors Service or A by Standard & Poor.

Restricted cash at September 30, 2016 includes $10.0 million in a money market account, held in connection with the Company’s notes payable and $353,000 in cash accounts held as collateral primarily under the terms of an office operating lease.

Fair Value of Financial Instruments

The carrying values of cash equivalents, accounts receivable, interest receivable, accounts payable, and certain accrued expenses at September 30, 2016 and December 31, 2015, approximate their fair values due to the short-term nature of these items. The Company’s notes payable balance approximates fair value as of September 30, 2016 and December 31, 2015 as the interest rates on the notes payable approximate the rates available to the Company as of these dates.

2. Summary of Significant Accounting Policies (Continued)

Concentrations and Credit Risk

The Company’s principal financial instruments subject to potential concentration of credit risk are cash and cash equivalents and investments held in money market accounts. The Company places cash deposits with a federally insured financial institution. The Company maintains its cash at banks and financial institutions it considers to be of high credit quality; however, the Company’s cash deposits may at times exceed the FDIC insured limit. Balances in excess of federally insured limitations may not be insured. The Company has not experienced losses on these accounts, and management believes that the Company is not exposed to significant risks on such accounts.

The Company’s accounts receivable are derived from net revenue to customers and distributors located throughout the world. The Company evaluates its customers’ financial condition and, generally, requires no collateral from its customers. The Company provides reserves for potential credit losses but has not experienced significant losses to date. The Company had one customer who constituted 100% of the Company’s net accounts receivable at September 30, 2016 and December 31, 2015.

Accounts Receivable

Accounts receivable are recorded at net realizable value, which includes an allowance for estimated uncollectable accounts. The allowance for uncollectible accounts was determined based on historical collection experience.

Inventories

Inventories are stated at the lower of cost or market, on a first-in, first-out basis. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis. Any inventory on hand at the measurement date in excess of the Company’s current requirements based on anticipated levels of sales is classified as long-term on the Company’s consolidated balance sheets. The Company’s classification of long-term inventory requires it to estimate the portion of on-hand inventory that can be realized over the next 12 months.

Identifiable Intangible Assets and Goodwill

Identifiable intangible assets are recorded at cost, or when acquired as part of a business acquisition, at estimated fair value. Certain intangible assets are amortized over 7 to 10 years. Similar to tangible personal property and equipment, the Company periodically evaluates identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Intellectual property consists of purchased patent rights and developed research and development acquired as part of a business acquisition. Amortization of the patent rights is recorded using the straight-line method over the estimated useful life of the patents of 10 years. Amortization of the developed research and development is recorded using the straight-line method over the estimated useful life of 7 years. This method approximates the period over which the Company expects to receive the benefit from these assets. See Note 10 for additional information related to the write-off of purchased patents in connection with the restructuring plan executed in May 2016. No impairment existed at December 31, 2015.

Indefinite-lived intangible assets, such as goodwill, are not amortized. The Company tests the carrying amounts of goodwill for recoverability on an annual basis at December 31 or when events or changes in circumstances indicate evidence a potential impairment exists, using a fair value based test. The Company continues to operate in one segment, which is considered to be the sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. See Note 10 for additional information related to goodwill impairment recorded during the second quarter of 2016. No impairment existed at December 31, 2015.

2. Summary of Significant Accounting Policies (Continued)

In-Process Research and Development

In-process research and development (“IPR&D”) assets represent the fair value assigned to technologies that were acquired, which at the time of acquisition have not reached technological feasibility and have no alternative future use. IPR&D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development projects. During the period that the IPR&D assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if the Company becomes aware of any events occurring or changes in circumstances that indicate that the fair value of the IPR&D assets are less than their carrying amounts. If and when development is complete, which generally occurs upon regulatory approval, and the Company is able to commercialize products associated with the IPR&D assets, these assets are then deemed definite-lived and are amortized based on their estimated useful lives at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&D assets, calculated as the excess of carrying value of the IPR&D assets over fair value. The IPR&D was acquired on September 21, 2015. No impairment existed at September 30, 2016 and December 31, 2015.

Property and Equipment

Property and equipment consists primarily of machinery, manufacturing equipment, computer equipment, furniture, and leasehold improvements, which are recorded at cost.

Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:

Machinery and manufacturing equipment		3-5 years
Computer equipment		3 years
Furniture		5 years
Leasehold improvements		Lesser of lease term or 3 to 10 years

Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.

Impairment of Long-Lived Assets

The Company reviews its long-lived assets for possible impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine the recoverability of its long-lived assets, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the long-lived assets, then such assets are written down to their fair value. The Company’s estimates of anticipated cash flows and the remaining estimated useful lives of long-lived assets could be reduced in the future, resulting in a reduction to the carrying amount of long-lived assets.

Contingent Consideration

Contingent consideration is recorded as a liability and is the estimate of the fair value of potential milestone payments related to business acquisitions. Contingent consideration is measured at fair value using a discounted cash flow model utilizing significant unobservable inputs including the probability of achieving each of the potential milestones and an estimated discount rate associated with the risks of the expected cash flows attributable to the various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected timelines for achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The fair value of the contingent consideration at each reporting date is updated by reflecting the changes in fair value in our statement of operations and comprehensive loss.

Translation of Foreign Currencies

The functional currency of the Company’s operational foreign subsidiaries is Euros. The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for a subsidiary using a functional currency other than the U.S. dollar is included in accumulated other comprehensive income or loss as a separate component of stockholders’ equity.

2. Summary of Significant Accounting Policies (Continued)

The Company’s intercompany accounts are denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation adjustment in accumulated other comprehensive income or loss as a separate component of stockholders’ equity, while gains and losses resulting from the remeasurement of intercompany receivables from a foreign subsidiary for which the Company anticipates settlement in the foreseeable future are recorded in the consolidated statement of operations and comprehensive loss. The net gains and losses included in net loss in the consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2016 and 2015 were not significant.

Business Acquisitions

Business acquisitions are accounted for using the acquisition method of accounting in accordance with ASC 805, “Business Combinations.” ASC 805 requires, among other things, that assets acquired and liabilities assumed be recognized at their fair values, as determined in accordance with ASC 820, “Fair Value Measurements,” as of the acquisition date. For certain assets and liabilities, book value approximates fair value. In addition, ASC 805 establishes that consideration transferred be measured at the closing date of the acquisition at the then-current market price. Under ASC 805, acquisition related costs (i.e., advisory, legal, valuation and other professional fees) and certain acquisition-related restructuring charges impacting the target company are expensed in the period in which the costs are incurred. The application of the acquisition method of accounting requires the Company to make estimates and assumptions related to the estimated fair values of net assets acquired.

Significant judgments are used during this process, particularly with respect to intangible assets. Generally, intangible assets are amortized over their estimated useful lives. Goodwill and other indefinite-lived intangibles are not amortized, but are annually assessed for impairment. Therefore, the purchase price allocation to intangible assets and goodwill has a significant impact on future operating results.

Risk and Uncertainties

The Company is subject to a number of risks similar to other similarly-sized companies in the medical device industry. These risks include, without limitation, the historical lack of profitability; the Company’s ability to raise additional capital; its ability to successfully integrate the Senhance System into its business; its ability to successfully develop, clinically test and commercialize its products; the timing and outcome of the regulatory review process for its products; changes in the health care and regulatory environments of the United States, Italy, other countries in the European Union, and other countries in which the Company intends to operate; its ability to attract and retain key management, marketing and scientific personnel; competition from new entrants; its ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights; its ability to successfully transition from a research and development company to a marketing, sales and distribution concern; competition in the market for robotic surgical devices; and its ability to identify and pursue development of additional products.

Revenue Recognition

The Company’s revenue consists of product revenue resulting from the sales of systems, instruments and accessories, and service revenue. The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable, and collectability is reasonably assured. Revenue is presented net of taxes collected from customers that are remitted to government authorities. The Company generally recognizes revenue at the following points in time:

•System sales. For systems sold directly to end customers, revenue is recognized when acceptance occurs, which is deemed to have occurred upon customer acknowledgment of delivery or installation, depending on the terms of the arrangement. The Senhance Systems are delivered with a software component. However, because the software and non-software elements function together to deliver the system’s essential functionality, the Company's arrangements are excluded from being accounted for under software revenue recognition guidance.

•Instruments and accessories. Revenue from sales of instruments and accessories is generally recognized at the time of shipment.

•Service. Service revenue is recognized ratably over the term of the service period. Revenue related to services performed on a time-and-materials basis is recognized when it is earned and billable.

2. Summary of Significant Accounting Policies (Continued)

The Company's system sale arrangements contain multiple elements including a system(s), instruments, accessories, and system service. The Company generally delivers all of the elements, other than service, within days of entering into the system sale arrangement. Each of these elements is a separate unit of accounting. System accessories, instruments, accessories and service are also sold on a stand-alone basis.

For multiple-element arrangements, revenue is allocated to each unit of accounting based on their relative selling prices. Relative selling prices are based first on vendor specific objective evidence of fair value (“VSOE”), then on third-party evidence of selling price (“TPE”) when VSOE does not exist, and then on management's best estimate of the selling price (“BESP”) when VSOE and TPE do not exist.

The Company’s system sale arrangements generally include a one-year period of free service, and the right for the customer to purchase service annually thereafter. The revenue allocated to the free service period is deferred and recognized ratably over the free service period. Deferred revenue was primarily comprised of deferred revenue related to service contracts for the periods presented.

Because the Company has neither VSOE nor TPE for its systems, the allocation of revenue is based on BESP for the systems sold. The objective of BESP is to determine the price at which the Company would transact a sale, had the product been sold on a stand-alone basis. The Company determines BESP for its systems by considering multiple factors, including, but not limited to, features and functionality of the system, geographies, type of customer, and market conditions. The Company regularly reviews BESP and maintains internal controls over establishing and updating these estimates.

Research and Development Costs

Research and development expenses primarily consist of engineering, product development and regulatory expenses, incurred in the design, development, testing and enhancement of our products and legal services associated with our efforts to obtain and maintain broad protection for the intellectual property related to our products. Research and development costs are expensed as incurred.

Stock-Based Compensation

The Company follows ASC 718 (“Stock Compensation”) and ASC 505-50 (“Equity-Based Payments to Non-employees”), which provide guidance in accounting for share-based awards exchanged for services rendered and requires companies to expense the estimated fair value of these awards over the requisite service period. For awards granted to non-employees, the Company determines the fair value of the stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of either (1) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty’s performance is complete.

The Company recognizes compensation expense for stock-based awards based on estimated fair values on the date of grant for awards granted to employees. The Company uses the Black-Scholes-Merton option pricing model to determine the fair value of stock options. The fair value of restricted stock units is determined by the market price of the Company’s common stock on the date of grant. The expense associated with stock-based compensation is recognized on a straight-line basis over the requisite service period of each award.

The Company records as expense the fair value of stock-based compensation awards, including stock options and restricted stock units. Compensation expense for stock-based compensation was approximately $3,858,000 and $2,388,000 for the nine months ended September 30, 2016 and 2015, respectively.

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets or liabilities for the temporary differences between financial reporting and tax basis of the Company’s assets and liabilities, and for tax carryforwards at enacted statutory rates in effect for the years in which the asset or liability is expected to be realized. The effect on deferred taxes of a change in tax rates is recognized in income during the period that includes the enactment date. In addition, valuation allowances are established when necessary to reduce deferred tax assets and liabilities to the amounts expected to be realized.

2. Summary of Significant Accounting Policies (Continued)

Comprehensive Loss

Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.

Segments

The Company operates in one business segment—the research, development and sale of medical device robotics to improve minimally invasive surgery. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. Approximately 53% of the Company’s total consolidated assets are located within the U.S. as of September 30, 2016. The remaining assets are mostly located in Europe and are primarily related to the Company’s facility in Italy, and include goodwill, intellectual property, in-process research and development, other current assets and inventory of $93.3 million at September 30, 2016, associated with the Senhance Acquisition in September 2015. Total assets outside of the U.S. excluding goodwill amounted to 37% of total consolidated assets at September 30, 2016.

Impact of Recently Issued Accounting Standards

In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230)” which addresses changes to reduce the presentation diversity of certain cash receipts and cash payments in the statement of cash flows, including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, and distributions received from equity method investees. The guidance becomes effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The new standard will be applied retrospectively, but may be applied prospectively if retrospective application would be impracticable. The Company is currently evaluating the new guidance and has not determined the impact this standard may have on its consolidated statement of cash flows.

In March 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-09, Compensation – Stock Compensation (Topic 718) – Improvements to Employee Share-Based Payment Accounting. Under ASU 2016-09, the tax effects of stock compensation will be recognized as income tax expense or benefit in the income statement and the tax effects of exercised or vested awards will be treated as discrete items in the reporting period in which they occur. Along with other income tax cash flows, excess tax benefits will be classified as operating activities, and cash paid by an employer when directly withholding shares for tax withholding purposes will be classified as financing activities. Entities may make an entity-wide accounting policy election to either estimate the number of awards that are expected to vest (current GAAP) or account for forfeitures when they occur. The threshold to qualify for equity classification permits withholding up to the maximum statutory tax rates in the applicable jurisdictions. For public companies, ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted, however, an entity that elects early adoption must adopt all amendments under the new standard in the same period. The Company is currently evaluating the impact of the amended guidance on our consolidated financial statements.

In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. We are currently evaluating the impact of our pending adoption of the new standard on our consolidated financial statements.

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09). The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. In August 2015, the FASB issued an update to defer the effective date of this update by one year. The updated standard becomes effective for the Company in the first quarter of fiscal year 2018, but allows the Company to adopt the standard one year earlier if it so chooses. The Company has not yet selected a transition method and is currently evaluating the effect that the updated standard will have on its Consolidated Financial Statements and related disclosures.

2. Summary of Significant Accounting Policies (Continued)

Except as noted above, there have been no significant changes to our assessment of the impact of recently issued accounting standards included in Note 2 of Notes to Consolidated Financial Statements in our Fiscal 2015 Form 10-K.

Reclassifications

As a result of a recent acquisition, certain financial statement captions have been added and we have reclassified certain prior-period amounts on our consolidated statement of operations and comprehensive loss to conform to the presentation for the current period. Such reclassifications have no effect on previously reported total assets, liabilities, stockholders’ equity or net loss.

Acquisition of Senhance Surgical Robotic System

9 Months Ended

Sep. 30, 2016

Business Combinations [Abstract]

Acquisition of Senhance Surgical Robotic System

3. Acquisition of Senhance Surgical Robotic System

On September 21, 2015, the Company completed the strategic acquisition, through its wholly owned subsidiary TransEnterix International, from SOFAR, of all of the assets, employees and contracts related to the advanced robotic system for minimally invasive laparoscopic surgery now known as the Senhance System and changed the name of the acquired company from Vulcanos S.r.l. to TransEnterix Italia S.r.l.

Under the terms of the Purchase Agreement, the consideration consisted of the issuance of 15,543,413 shares of the Company’s common stock (the “Securities Consideration”) and approximately $25.0 million U.S. Dollars and €27.5 million Euro in cash consideration (the “Cash Consideration”). The Securities Consideration was issued in full at the closing of the Senhance Acquisition; the Cash Consideration was or will be paid in four tranches, as follows:

(1) $25.0 million of the Cash Consideration was paid at closing;

(2) The second tranche of the Cash Consideration (the “Second Tranche”) of €10.0 million shall be payable after the achievement of both of the following milestones (i) the earlier of approval from the FDA for the Senhance System or December 31, 2016, and (ii) the Company having cash on hand of at least $50.0 million, or successfully completing a financing, raising at least $50.0 million in gross proceeds; with payment of simple interest at a rate of 9.0% per annum between the achievement of the first milestone event and the payment date;

(3) The third tranche of the Cash Consideration (the “Third Tranche”) of €15.0 million shall be payable upon achievement of trailing revenues from sales or services contracts of the Senhance System of at least €25.0 million over a calendar quarter; and

(4) The fourth tranche of the Cash Consideration of €2.5 million shall be payable by December 31, 2016 as reimbursement for certain debt payments made by SOFAR under an existing SOFAR loan agreement.

The Third Tranche will be payable even if the Second Tranche is not then payable. In addition, the Second Tranche and Third Tranche payments will be accelerated in the event that (i) the Company or TransEnterix International is acquired, (ii) the Company significantly reduces or suspends selling efforts of the Senhance System, or (iii) the Company acquires a business that offers alternative products that are directly competitive with the Senhance System.

Under the Purchase Agreement, 10% of the Securities Consideration was being held in escrow to support SOFAR’s representations and warranties under the Purchase Agreement. In accordance with a related escrow agreement, the escrowed shares were released in September 2016. The Company, a subsidiary and SOFAR also entered into a Security Agreement, which provides that 10% of the membership interests of TransEnterix Italia have a lien placed thereon by and in favor of SOFAR to support the Company’s representations and warranties under the Purchase Agreement. The security interest period is twenty-four months after the closing of the Senhance Acquisition.

The Purchase Agreement contains customary representations and warranties of the parties and the parties have customary indemnification obligations, which are subject to certain limitations described further in the Purchase Agreement.

In connection with the Senhance Acquisition, the Company also entered into a Registration Rights Agreement, dated as of September 21, 2015, with SOFAR, pursuant to which the Company agreed to register the Securities Consideration shares for resale following the end of the lock-up periods described below. The resale registration statement has been filed and is effective, pending lapse of the lock-up restrictions as described below.

3. Acquisition of Senhance Surgical Robotic System (Continued)

In connection with the Senhance Acquisition, SOFAR entered into a Lock-Up Agreement with the Company pursuant to which SOFAR agreed, subject to certain exceptions, not to sell, transfer or otherwise convey any of the Securities Consideration for one year following the Closing Date. On September 21, 2016, fifty percent of the Securities Consideration was released from the lock-up restrictions and is eligible to be resold under the effective resale registration statement. With respect to the remaining fifty percent of the Securities Consideration, the Lock-up Agreement provides that an additional twenty-five percent of the Securities Consideration remains locked-up until the eighteen-month anniversary of the Closing Date, and the remaining twenty-five percent of the Securities Consideration remains locked-up until the two-year anniversary of the Closing Date. The restrictions on transfer contained in the Lock-up Agreement cease to apply to all of the Securities Consideration following the second anniversary of the Closing Date, or earlier upon certain other conditions.

The Senhance Acquisition was accounted for as a business combination utilizing the methodology prescribed in ASC 805. The purchase price for the Senhance Acquisition has been allocated to the assets acquired and liabilities assumed based on their estimated fair values.

The Senhance Acquisition-date fair value of the consideration is as follows (in thousands, except for per share amounts):

Common shares issued		15,543
Closing price per share	$	2.81
	$	43,677
Cash consideration		25,000
Contingent consideration		23,900
Total consideration	$	92,577

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed on September 21, 2015, the date of acquisition (in thousands):

Accounts receivable	$	78
Inventories		2,800
Current deferred tax asset		526
Other current assets		4,180
Property and equipment		1,384
Intellectual property		48,500
In-process research and development		17,100
Goodwill		38,348
Total assets acquired	$	112,916
Accounts payable and other liabilities		1,915
Long-term deferred tax liabilities		18,424
Net assets acquired	$	92,577

The Company allocated $48.5 million of the purchase price to identifiable intangible assets of intellectual property that met the separability and contractual legal criterion of ASC 805. The intellectual property is being amortized using the straight-line method over 7 years.

IPR&D is principally the estimated fair value of the Senhance System technology which had not reached commercial technological feasibility nor had alternative future use at the time of the acquisition and therefore the Company considered IPR&D, with assigned values to be allocated among the various IPR&D assets acquired.

Goodwill is calculated as the difference between the acquisition-date fair value of the consideration transferred and the fair values of the assets acquired and liabilities assumed. The goodwill resulting from this acquisition arises largely from synergies expected from combining the operations of TransEnterix Italia with the Company’s existing operations. The goodwill is not deductible for income tax purposes.

3. Acquisition of Senhance Surgical Robotic System (Continued)

All legal, consulting and other costs related to the acquisition, aggregating approximately $4.2 million, have been expensed as incurred and are included in operating expenses in the Company’s consolidated statement of operations and comprehensive loss for the year ended December 31, 2015. The results of operations for TransEnterix Italia are included in the Company’s consolidated statements of operations and comprehensive loss for the period from the September 21, 2015 acquisition date.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Cash, Cash Equivalents and Restricted Cash

9 Months Ended

Sep. 30, 2016

Cash And Cash Equivalents [Abstract]

Cash, Cash Equivalents and Restricted Cash

4. Cash, Cash Equivalents and Restricted Cash

Cash, cash equivalents and restricted cash consist of the following:

	September 30,		December 31,
	2016		2015
	(In thousands)
	(unaudited)
Cash	$	2,366	$	1,666
Money market		40,152		36,783
Total cash and cash equivalents	$	42,518	$	38,449
Restricted cash	$	10,353	$	—
Total	$	52,871	$	38,449

- Definition

The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.

+ References + Details

Fair Value

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Fair Value

5. Fair Value

The Company held certain assets and liabilities that are required to be measured at fair value on a recurring basis. These assets and liabilities include available for sale securities classified as cash and cash equivalents, restricted cash and contingent consideration. ASC 820-10 (“Fair Value Measurement Disclosure”) requires the valuation using a three-tiered approach, which requires that fair value measurements be classified and disclosed in one of three tiers. These tiers are: Level 1, defined as quoted prices in active markets for identical assets or liabilities; Level 2, defined as valuations based on observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable input data; and Level 3, defined as valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants.

For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data and therefore, are based primarily upon estimates, are often calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, the results cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique, and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the results of current or future values. The Company utilizes fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures.

As prescribed by U.S. GAAP, the Company groups assets and liabilities at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. An adjustment to the pricing method used within either Level 1 or Level 2 inputs could generate a fair value measurement that effectively falls in a lower level in the hierarchy.

The determination of where an asset or liability falls in the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures and based on various factors, it is possible that an asset or liability may be classified differently from period to period. However, the Company expects changes in classifications between levels will be rare.

The carrying values of accounts receivable, inventories, interest receivable, accounts payable, and certain accrued expenses at September 30, 2016 and December 31, 2015, approximate their fair values due to the short-term nature of these items. The Company’s notes payable balance also approximates fair value as of September 30, 2016 and December 31, 2015, as they were modified in the third quarter of 2015.

5. Fair Value (Continued)

The following are the major categories of assets measured at fair value on a recurring basis as of September 30, 2016 and December 31, 2015, using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3):

	September 30, 2016
	(In thousands)
	(unaudited)
Description	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets measured at fair value
Cash and cash equivalents	$	42,518	$	—	$	—	$	42,518
Restricted cash		10,353		—		—		10,353
Total Assets measured at fair value	$	52,871	$	—	$	—	$	52,871
Liabilities measured at fair value
Contingent consideration	$	—	$	—	$	25,200	$	25,200
Total liabilities measured at fair value	$	—	$	—	$	25,200	$	25,200

	December 31, 2015
	(In thousands)
Description	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets measured at fair value
Cash and cash equivalents	$	38,449	$	—	$	—	$	38,449
Total Assets measured at fair value	$	38,449	$	—	$	—	$	38,449
Liabilities measured at fair value
Contingent consideration	$	—	$	—	$	23,500	$	23,500
Total liabilities measured at fair value	$	—	$	—	$	23,500	$	23,500

The Company’s financial liabilities consisted of contingent consideration potentially payable to SOFAR related to the Senhance Acquisition in September 2015 (Note 3). This liability is reported as Level 3 as estimated fair value of the contingent consideration related to the acquisition requires significant management judgment or estimation and is calculated using the income approach, using various revenue and cost assumptions and applying a probability to each outcome. The change in fair value of the contingent consideration of $1,700,000 for the nine months ended September 30, 2016 was primarily due to the effect of the passage of time on the fair value measurement and the impact of foreign currency exchange rates. Adjustments associated with the change in fair value of contingent consideration are included in the Company’s consolidated statements of operations and comprehensive loss.

The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements classified in Level 3 as of September 21, 2015, December 31, 2015, and September 30, 2016:

Valuation

Methodology

Significant

Unobservable Input

Weighted Average

(range, if

applicable)

Contingent consideration

Probability weighted

income approach

Milestone dates

2016 to 2017

Discount rate

Probability of occurrence

7.5% to 9.0%

100%

5. Fair Value (Continued)

The following table summarizes the change in fair value, as determined by Level 3 inputs, for all assets and liabilities using unobservable Level 3 inputs for the nine months ended September 30, 2016:

	Fair Value Measurement at Reporting Date (Level 3)
	(In thousands)
	(unaudited)
Balance at December 31, 2015	$	23,500
Change in fair value		1,700
Balance at September 30, 2016	$	25,200
Current portion		11,325
Long-term portion		13,875
Balance at September 30, 2016	$	25,200

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Accounts Receivable, Net

9 Months Ended

Sep. 30, 2016

Receivables [Abstract]

Accounts Receivable, Net

6. Accounts Receivable, Net

The following table presents the components of accounts receivable:

	September 30,			December 31,
	2016			2015
	(In thousands)
	(unaudited)
Gross accounts receivable	$	968		$	76
Allowance for uncollectible accounts		(78	)		—
Total accounts receivable, net	$	890		$	76
Short-term portion	$	616		$	76
Long-term portion		274			—
Total accounts receivable	$	890		$	76

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

Inventories

9 Months Ended

Sep. 30, 2016

Inventory Disclosure [Abstract]

Inventories

7. Inventories

The components of inventories are as follows:

	September 30,		December 31,
	2016		2015
	(In thousands)
	(unaudited)
Finished goods	$	2,250	$	2,704
Raw materials		—		1,928
Total inventories	$	2,250	$	4,632
Short-term portion	$	2,250	$	3,923
Long-term portion		—		709
Total inventories	$	2,250	$	4,632

As disclosed in Note 14, the Company executed a restructuring plan in May 2016 and wrote down inventory related to the SurgiBot System. The write down of inventory of $2.6 million is included in the accompanying consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2016. There were no such write-downs for the nine month periods ended September 30, 2015.

Other Current Assets

9 Months Ended

Sep. 30, 2016

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Other Current Assets

8. Other Current Assets

The following table presents the components of other current assets:

	September 30,		December 31,
	2016		2015
	(In thousands)
	(unaudited)
Advances to vendors	$	5,714	$	5,403
Prepaid expenses		2,060		750
Other receivables		375		536
Total	$	8,149	$	6,689

Property and Equipment

9 Months Ended

Sep. 30, 2016

Property Plant And Equipment [Abstract]

Property and Equipment

9. Property and Equipment

Property and equipment consisted of the following:

	September 30,			December 31,
	2016			2015
	(In thousands)
	(unaudited)
Machinery and manufacturing equipment	$	6,357		$	5,846
Computer equipment		2,052			1,875
Furniture		448			374
Leasehold improvements		1,898			1,700
Total property and equipment		10,755			9,795
Accumulated depreciation and amortization		(6,141	)		(5,387	)
Property and equipment, net	$	4,614		$	4,408

As disclosed in Note 14, the Company executed a restructuring plan in May 2016 and disposed of certain long-lived assets, primarily equipment and fixtures related to the SurgiBot System. The disposal of long-lived assets of $1.0 million is included as a component of restructuring and other charges in the accompanying consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2016. There were no such disposals for the nine months ended September 30, 2015.

Depreciation expense was $1,498,000 and $802,000 for the nine months ended September 30, 2016 and 2015, respectively.

Goodwill, In-Process Research and Development and Intellectual Property

9 Months Ended

Sep. 30, 2016

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill, In-Process Research and Development and Intellectual Property

10. Goodwill, In-Process Research and Development and Intellectual Property

Goodwill

Goodwill of $93.8 million was recorded in connection with the Merger, as described in Note 1, and goodwill of $38.3 million was recorded in connection with the Senhance Acquisition, as described in Note 3. The carrying value of goodwill and the change in the balance for the nine months ended September 30, 2016 is as follows:

	Goodwill
	(In thousands)
	(unaudited)
Balance at December 31, 2015	$	130,869
Foreign currency translation impact		863
Impairment loss		(61,784	)
Balance at September 30, 2016	$	69,948

10. Goodwill, In-Process Research and Development and Intellectual Property (Continued)

The Company performs an annual impairment test of goodwill at December 31, or more frequently if events or changes in circumstances indicates that the carrying value of the Company’s one reporting unit may not be recoverable. During the second quarter of 2016, the FDA notified the Company that the SurgiBot System did not meet the criteria for substantial equivalency, negatively impacting the Company’s market capitalization, and warranting an interim two-step quantitative impairment test. Goodwill is tested for impairment using a two-step approach. In the first step, the fair value of the reporting unit is determined and compared to the reporting unit's carrying value, including goodwill. If the fair value of the reporting unit is less than its carrying value, the second step of the goodwill impairment test is performed to measure the amount of impairment, if any. In the second step, the fair value of the reporting unit is allocated to the assets and liabilities of the reporting unit as if it had been acquired in a business combination and the purchase price was equivalent to the fair value of the reporting unit. The excess of the fair value of the reporting unit over the amounts assigned to its assets and liabilities is referred to as the implied fair value of goodwill. The implied fair value of the reporting unit's goodwill is then compared to the actual carrying value of goodwill. If the implied fair value of goodwill is less than the carrying value of goodwill, an impairment loss is recognized for the difference.

The Company determined the fair value of the reporting unit using a discounted cash flow analysis derived from the Company’s long-term plans. The fair value of the reporting unit was corroborated using market prices for TransEnterix, Inc. The inputs used to determine the fair values were classified as Level 3 in the fair value hierarchy. Based on the impairment test, the Company recorded goodwill impairment of $61.8 million during the second quarter of 2016. No impairment was recorded as of December 31, 2015.

In-Process Research and Development

As described in Note 3, on September 21, 2015, the Company acquired all of the assets related to the Senhance System and recorded $17.1 million of IPR&D. The estimated fair value of the IPR&D was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flows were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the acquisition date and the time and resources needed to complete development. The Company used a discount rate of 45% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.

The carrying value of the Company’s IPR&D assets and the change in the balance for the nine months ended September 30, 2016 is as follows:

	In-Process Research and Development (In thousands)
	(unaudited)
Balance at December 31, 2015	$	16,511
Foreign currency translation impact		461
Balance at September 30, 2016	$	16,972

Intellectual Property

In 2009, the Company purchased certain patents from an affiliated company for $5.0 million in cash and concurrently terminated a license agreement related to the patents. The patent expiration dates begin in 2027. In addition, as described in Note 3, on September 21, 2015, the Company acquired all of the developed technology related to the Senhance System and recorded $48.5 million of intellectual property. The estimated fair value of the intellectual property was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flows were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the acquisition date and the time and resources needed to complete development. The Company used a discount rate of 45% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.

As disclosed in Note 14, the Company executed a restructuring plan in May 2016 and wrote-off certain intellectual property consisting of patents related to the SurgiBot System. The write-off of intellectual property of $1.6 million is included as a component of restructuring and other charges in the accompanying consolidated statements of operations and comprehensive losses for the nine months ended September 30, 2016. There were no such write offs for the nine months ended September 30, 2015.

10. Goodwill, In-Process Research and Development and Intellectual Property (Continued)

The components of gross intellectual property, accumulated amortization, and net intellectual property as of September 30, 2016 and December 31, 2015 are as follows:

	September 30, 2016													December 31, 2015
	(In thousands)													(In thousands)
	Gross Carrying Amount		Accumulated Amortization			Foreign currency translation impact			Write-off			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Foreign currency translation impact			Net Carrying Amount
Patents	$	5,000	$	(3,438	)	$	—		$	(1,562	)	$	—	$	5,000	$	(3,259	)	$	—		$	1,741
Developed technology		48,500		(6,803	)		(437	)		—			41,260		48,500		(1,672	)		(1,671	)		45,157
Total intellectual property	$	53,500	$	(10,241	)	$	(437	)	$	(1,562	)	$	41,260	$	53,500	$	(4,931	)	$	(1,671	)	$	46,898

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes Income taxes have been accounted for using the liability method in accordance with ASC 740 “Income Taxes”. The Company computes its interim provision for income taxes by applying the estimated annual effective tax rate method. The Company estimates an annual effective tax rate of 5.1% for the year ending December 31, 2016. This rate does not include the impact of any discrete items. The Company incurred losses for the three and nine month periods ended September 30, 2016 and is forecasting additional losses through the year, resulting in an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2016. Due to the Company’s history of losses, there is not sufficient evidence to record a net deferred tax asset associated with the U.S. operations and accordingly a full valuation allowance has been recorded related to the net deferred tax asset in that jurisdiction. Deferred tax assets and liabilities related to the TransEnterix Italia subsidiary have been recorded as a component of purchase accounting as of the acquisition date. The deferred tax benefit during the nine months ended September 30, 2016 of approximately $4.7 million includes an immaterial adjustment of approximately $1.7 million to the deferred tax liability of TransEnterix Italia which relates to a change in the Italian income tax rate in December 2015. There is no net deferred tax asset recorded in relation to TransEnterix Italia and accordingly no valuation allowance has been recorded in that jurisdiction. The Company’s effective tax rate for each of the nine month periods ended September 30, 2016 and 2015 was 4.3% and 0%, respectively. The effective tax rate for September 30, 2016 includes the tax effect of the Company’s goodwill impairment charge, which is being treated as a discrete item for the quarter ending June 30, 2016. At September 30, 2016, the Company had no unrecognized tax benefits that would affect the Company’s effective tax rate.

Accrued Expenses

9 Months Ended

Sep. 30, 2016

Accrued Liabilities Current [Abstract]

Accrued Expenses

12. Accrued Expenses

The following table presents the components of accrued expenses:

	September 30,		December 31,
	2016		2015
	(In thousands)
	(unaudited)
Taxes and other assessments	$	3,220	$	3,112
Compensation and benefits		1,718		2,492
Interest and final payment fee		881		411
Deferred rent		301		278
Consulting and other vendors		776		553
Legal and professional fees		226		268
Restructuring charges		49		—
Other		75		281
Total	$	7,246	$	7,395

Notes Payable	9 Months Ended
Notes Payable	Sep. 30, 2016
Debt Disclosure [Abstract]
Notes Payable	13. Notes Payable On January 17, 2012, TransEnterix Surgical entered into a loan and security agreement with Silicon Valley Bank and Oxford Finance LLC (the “Lenders”). The terms of the Original Loan Agreement provided for two term loans in aggregate of $10,000,000 comprised of a $4,000,000 term loan and a $6,000,000 term loan. In connection with the Merger, the Company assumed and became the borrower under TransEnterix Surgical’s Original Loan Agreement, and agreed to amendments to the Original Loan Agreement, dated as of September 3, 2013 and October 31, 2013, respectively. The Original Loan Agreement had a maturity date of January 1, 2016 and a fixed interest rate of 8.75% per annum. As of September 26, 2014, the outstanding principal amount of the Original Loan Agreement was $5,604,000. On September 26, 2014, the Company entered into the Amended and Restated Loan Agreement with the Lenders. Under the Amended and Restated Loan Agreement, the Lenders agreed to make certain term loans (the “Amended and Restated Term Loans”) in an aggregate principal amount of up to $25,000,000. The first tranche of the Amended and Restated Term Loans increased the Company’s borrowings at September 26, 2014 from $5,604,000 to $10,000,000. The Amended and Restated Term Loans allowed for interest-only payment at 7.5% per annum through October 31, 2015 and a maturity date of April 1, 2018. On August 14, 2015, the Company entered into the First Amendment to the Amended and Restated Loan Agreement (the “First Amendment”) with the Lenders. The first tranche of the First Amendment increased the Company’s borrowings at August 14, 2015 from $10,000,000 to $20,000,000. The First Amendment allowed for interest-only payments at 7.5% per annum through April 30, 2016 and a maturity date of October 1, 2018. On September 18, 2015, in connection with entry into the Purchase Agreement with SOFAR S.p.A. (see Note 3 for a description of the related transactions), the Company and the Lenders entered into the Consent and Second Amendment to Amended and Restated Loan Agreement (the “Second Amendment”). The Second Amendment modified the period in which the Company can make interest-only payments at 7.5% per annum on the term loans until January 31, 2016. The Second Amendment has a maturity date of July 1, 2018. In connection with the entry into the loan agreements, the Company became obligated to pay final payment and facility fees. The final payment fee obligation paid under the Original Loan Agreement at 3.33% was $333,000 and the facility fee payment was $75,000. The final payment fee obligation paid under the Amended and Restated Loan Agreement at 5.45% was $165,920 and the facility fee was $90,000. The facility fee paid under the First Amendment was $90,000. The final payment fee obligation payable under the Second Amendment is 6.5% of the original principal amount of each term loan without the interest only extension and 8.0% with both interest-only extensions. In addition, in connection with the borrowings, the Company issued warrants to the Lenders to purchase shares of the Company’s common stock amounting to 279,588 warrants under the Original Loan Agreement, 38,324 warrants under the Amended and Restated Loan Agreement and 112,903 under the First Amendment. Additional warrants will be issued if additional tranche term loans are made. The warrants expire seven years from their respective issue date. The Amended and Restated Loan Agreement, as amended, is secured by a security interest in all assets of the Company and its current and future U.S. subsidiaries, including a security interest in intellectual property proceeds, but excluding a current security interest in intellectual property. The Amended and Restated Loan Agreement contains customary representations (tested on a continual basis) and covenants that, subject to exceptions, restrict the Company’s ability to do the following things: declare dividends or redeem or repurchase equity interests; incur additional liens; make loans and investments; incur additional indebtedness; engage in mergers, acquisitions, and asset sales; transact with affiliates; undergo a change in control; add or change business locations; and engage in businesses that are not related to its existing business. 13. Notes Payable (Continued) Further, under the Second Amendment, the Lenders consented to the formation of TransEnterix International, the entry of the Company into the Purchase Agreement and other transaction documents, and the name change of TransEnterix Italia. The Company agreed to pledge 100% of the common stock of TransEnterix International as additional security for the borrowings under the Amended and Restated Loan Agreement, as amended. The Second Amendment added a provision permitting the Company to transfer designated amounts to TransEnterix Italia during the term of the Amended and Restated Loan Agreement. This provision for the transfer of designated amount was amended on November 13, 2015 with the Third Amendment to the Amended and Restated Loan Agreement. On April 19, 2016, the Company and its U.S. subsidiaries entered into the Consent and Fourth Amendment to the Loan Agreement (the “Fourth Amendment”) pursuant to which TransEnterix International, joined the Loan Agreement and the existing promissory notes as a co-borrower thereunder and pledged, as collateral for the obligations under the Loan Agreement, substantially all of its non-intellectual property assets, including up to 65% of the equity interests owned by TransEnterix International in TransEnterix Europe S.Á.R.L, a wholly owned subsidiary of TransEnterix International. On September 7, 2016, the Company and its U.S. subsidiaries entered into the Fifth Amendment to the Loan Agreement (the “Fifth Amendment”). The Fifth Amendment provides more flexibility to the Company with respect to its intercompany activities with its foreign subsidiaries and adds an affirmative covenant requiring the Company to maintain a $10.0 million cash balance in accounts held with the Lender. Cash amounts related to this requirement are included in restricted cash on the consolidated balance sheet. In accordance with ASC 470-50 Debt – Modifications and Extinguishments, it was determined that the debt refinancing on September 26, 2014, was considered to be a debt modification. Accordingly, the Company recorded approximately $129,000 of debt discount, consisting of the $75,000 facility fee and the relative fair value of warrants on the issue date of $54,000. Additionally, approximately $30,000 of legal fees were recorded as a result of the transaction. The debt discount and deferred financing costs will be amortized over the life of the new debt agreement using the effective interest method into interest expense, net. In accordance with ASC 470-50 Debt – Modifications and Extinguishments, it was determined that the debt refinancings on August 14, 2015, September 18, 2015, April 19, 2016 and September 7, 2016 were considered to be debt modifications. Additionally, during the third quarter of 2015, the Company adopted ASU No. 2015-03, “Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. ASU 2015-03 requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt liability, consistent with the presentation of a debt discount. The Company recorded a debt discount of approximately $210,000 for these two amendments. Accordingly, the unamortized debt discount is presented as a reduction of the related debt liability in the Company’s balance sheet. In accordance with ASU 2015-03, this adopted guidance was applied retrospectively. The debt discount will be amortized over the life of the new debt agreement using the effective interest method into interest expense, net. In connection with the issuance of the notes payable and its amendments, TransEnterix Surgical incurred approximately $371,000 in debt issuance costs paid to lenders and third parties and $280,000 in debt issuance costs related to issuance of warrants to the lenders. The unamortized balance of $143,000 as of September 30, 2016 will be amortized using the effective interest method.

Restructuring	9 Months Ended
Restructuring	Sep. 30, 2016
Restructuring And Related Activities [Abstract]
Restructuring	14. Restructuring On April 19, 2016, the FDA notified the Company that the SurgiBot System did not meet the criteria for substantial equivalence based on the data submitted in the 510(k) submission. As a result, the Company has reprioritized its efforts to focus on the commercialization of and regulatory clearance for the Senhance System. Consequently, in May 2016, the Company implemented a restructuring plan. Under the restructuring plan, the Company reduced headcount, discontinued efforts on the SurgiBot System, and cancelled certain contracts. The restructuring charges amounted to $5.7 million, of which $2.6 million was included as inventory write down related to restructuring and $3.1 million was included as restructuring and other charges in the consolidated statements of operations and comprehensive loss, during the second quarter of 2016. The restructuring and other charges of $3.1 million included: (i) $0.5 million to be paid in cash, of which $0.4 million related to employee severance costs and $0.1 million related to cancellation of certain contracts; and (ii) $2.6 million for other non-cash charges, of which $1.0 million related to the disposal of long-lived assets for the abandonment of certain equipment and tooling directly relating to the SurgiBot System and $1.6 million related to the write-off of intellectual property for certain patents also relating to the SurgiBot System. The Company does not anticipate additional restructuring charges in 2016. The total future payments under the restructuring plan as of September 30, 2016 included in accrued expenses in the consolidated balance sheet as of September 30, 2016 are $49,000.

Public Offerings of Common Stock

9 Months Ended

Sep. 30, 2016

Text Block [Abstract]

Public Offerings of Common Stock

15. Public Offerings of Common Stock

On February 20, 2015, the Company entered into a Controlled Equity Offering^SM Sales Agreement (the “2015 Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), as sales agent, pursuant to which the Company sold through Cantor, from time to time, up to $25.0 million in shares of common stock in an at-the-market offering. All sales of shares were made pursuant to an effective shelf registration statement on Form S-3 filed with the SEC. The Company pays Cantor a commission of approximately 3% of the aggregate gross proceeds received from all sales of common stock under the Sales Agreement. Sales under the 2015 Sales Agreement have been fully sold as of February 9, 2016, with cumulative shares of 7,724,488, gross proceeds of $25.0 million and net proceeds of $24.0 million.

On June 11, 2015, the Company sold 16,666,667 shares of common stock at a public offering price of $3.00 per share for aggregate gross proceeds of $50 million in an underwritten firm commitment public offering. Net proceeds after issuance costs were $46.4 million. The closing of the public offering occurred on June 17, 2015. The Company granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 2,500,000 shares of Common Stock.

On July 10, 2015, the underwriters exercised a portion of their option to acquire an additional 2,075,000 shares at the public offering price of $3.00 per share for aggregate additional gross proceeds of $6.2 million. Net proceeds after issuance costs were $5.8 million. The purchase of the option shares closed on July 15, 2015. Total proceeds (including the option) were $52.2 million, net of issuance costs of $4.0 million. The common stock was offered and sold pursuant to the Shelf Registration Statement filed in November 2014 (the “November 2014 Shelf Registration Statement”), which was declared effective on December 19, 2014. The November 2014 Shelf Registration Statement allowed the Company to raise up to $100.0 million through the sale of debt securities, common stock, preferred stock, warrants, or any combination thereof. On March 3, 2016, the Company filed an amendment to the November 2014 Shelf Registration Statement increasing the amount available from $100.0 million to $150.0 million.

On February 9, 2016, the Company entered into a Controlled Equity Offering^SM Sales Agreement (the “2016 Sales Agreement”) with Cantor, as sales agent, pursuant to which the Company can sell through Cantor, from time to time, up to $43.6 million in shares of common stock in an at-the-market offering. All sales of shares have been and will continue to be made pursuant to an effective shelf registration statement on Form S-3 filed with the SEC. The Company pays Cantor a commission of approximately 3% of the aggregate gross proceeds received from all sales of common stock under the 2016 Sales Agreement. Unless otherwise terminated earlier, the 2016 Sales Agreement continues until all shares available under the Sales Agreement have been sold.

The following table summarizes the total sales under the 2015 Sales Agreement and 2016 Sales Agreement for the periods indicated (in thousands, except per share amounts):

	2015 Sales Agreement				2016 Sales Agreement
	Nine Months Ended September 30, 2016		Year Ended December 31, 2015		Nine Months Ended September 30, 2016
Total shares of common stock sold		5,710.2		2,014.3		8,763.4
Average price per share	$	3.23	$	3.25	$	4.70
Gross proceeds	$	18,454	$	6,546	$	41,156
Commissions earned by Cantor	$	553	$	197	$	1,235
Other issuance costs	$	—	$	259	$	185

On April 14, 2014, the Company sold 12,500,000 shares of common stock at a public offering price of $4.00 per share for aggregate gross proceeds of $50.0 million in an underwritten firm commitment public offering. Certain of the Company’s existing stockholders that are affiliated with certain of the Company’s directors purchased $10.0 million of common stock in the public offering. The closing of the public offering occurred on April 21, 2014. The Company granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 1,875,000 shares of Common Stock to cover over-allotments. On April 30, 2014, the underwriters exercised a portion of their over-allotment option to acquire an additional 1,610,000 shares at the public offering price of $4.00 per share for aggregate additional gross proceeds of $6.4 million. The purchase of the over-allotment shares closed on May 5, 2014. Total proceeds were $52.4 million, net of issuance costs of $4.0 million. The common stock was offered and sold pursuant to the Shelf Registration Statement filed in January 2014 (the “January 2014 Shelf Registration Statement”), which was declared effective on April 2, 2014. The January 2014 Shelf Registration Statement allowed the Company to raise up to $100.0 million through the sale of debt securities, common stock, preferred stock, warrants, or any combination thereof. As of September 30, 2016, the Company had $71.2 million available for future financings under such shelf registration statements.

Basic and Diluted Net Loss per Share	9 Months Ended
Basic and Diluted Net Loss per Share	Sep. 30, 2016
Earnings Per Share [Abstract]
Basic and Diluted Net Loss per Share	16. Basic and Diluted Net Loss per Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Diluted potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock. In computing diluted net loss per share for the nine months ended September 30, 2016 and 2015, no adjustment has been made to the weighted average outstanding common shares as the assumed exercise of outstanding options and warrants and conversion of preferred stock would be anti-dilutive.

Related Person Transactions	9 Months Ended
Related Person Transactions	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Person Transactions	17. Related Person Transactions Synergy Life Science Partners, L.P. and Synecor, LLC collectively owned approximately 5% and 6% of the Company’s common stock at September 30, 2016 and 2015, respectively. A member of the Company’s Board of Directors is managing partner of Synergy Life Science Partners, L.P. and an executive officer of Synecor, LLC. Various research and development services were purchased by the Company from Synecor LLC and its wholly owned subsidiary Synchrony Labs LLC pursuant to arms’ length terms approved by the Audit Committee and totaled approximately $5,000 and $434,000 for the nine months ended September 30, 2016 and 2015, respectively. On September 18, 2015, TransEnterix Italia entered into a six month service agreement for administrative expenses and rent with SOFAR, a shareholder that owned approximately 13.5% and 15.5% of the Company’s common stock at September 30, 2016 and 2015, respectively. Expenses under this agreement were approximately $162,000 and $0 for the nine months ended September 30, 2016 and 2015, respectively.

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	18. Commitments and Contingencies Contingent Consideration As discussed in Note 3, in September 2015, the Company completed the Senhance Acquisition using a combination of cash, stock and potential post-acquisition milestone payments. These milestone payments may be payable in the future, depending on the achievement of certain regulatory and commercial milestones. The maximum amount of the aggregate milestone payments could be €27.5 million. As of September 30, 2016, the fair value of the contingent consideration was $25.2 million. Legal Proceedings On June 2, 2016 a stockholder filed a putative class action complaint, Ashok V. Bankley, individually and on behalf of all others similarly situated vs. TransEnterix, Inc., Todd M. Pope and Joseph P. Slattery, in the United States District Court for the Eastern District of North Carolina (Case No. 5:16-cv-00313-D) (the “Initial Complaint”), against the Company and two of its executive officers on behalf of all persons who purchased or otherwise acquired the Company’s common stock between February 10, 2016 and May 10, 2016. On August 4, 2016, the defendants filed a motion to dismiss the Initial Complaint for failure to state a claim under the securities laws. On August 30, 2016, the court appointed Randall Clark, Samir Patel, the Underhill Cemetery Association, and the North Underhill Cemetery Association as the lead plaintiffs in the Initial Complaint, and also provided the plaintiffs an opportunity to amend the Initial Complaint. On September 26, 2016, the lead plaintiffs filed an Amended Complaint. Among other things, the Amended Complaint asserts revised claims against the Company and Messrs. Pope and Slattery, and adds claims against certain current and former members of the Company’s Board of Directors, and Cantor Fitzgerald & Co., the sales agent under the 2016 Sales Agreement, under which the Company offered and sold, through Cantor, shares of common stock in its 2016 ATM Offering. The Amended Complaint alleges that the defendants made false and misleading public statements related to the Company's SurgiBot System and its 510(k) application in violation of certain federal securities laws. The Amended Complaint seeks class certification of a class consisting of all persons who purchased or otherwise acquired the Company’s common stock between February 10, 2016 and May 10, 2016, class certification of a subclass of persons who purchased or otherwise acquired the Company’s common stock in connection with the 2016 ATM Offering between February 9, 2016 and April 19, 2016, unspecified monetary damages, costs, and attorneys’ fees. On November 8, 2016, the defendants moved to dismiss the Amended Complaint. On June 9, 2016, a different stockholder filed another putative class action complaint, Thomas Ravey, individually and on behalf of all others similarly situated vs. TransEnterix, Inc., Todd M. Pope and Joseph P. Slattery, in the United States District Court for the Middle District of North Carolina (Case No. 1:16-cv-599) (the “Ravey Action”). The Ravey Action asserted substantially similar claims against the same defendants and seeks substantially similar relief as the Initial Complaint. On August 4, 2016, the plaintiff in the Ravey Action voluntarily dismissed the Ravey Action. 18. Commitments and Contingencies (Continued) On July 8, 2016, a stockholder filed a putative derivative complaint, Otto Pikal v. Todd M. Pope, et al., in the General Court of Justice, Superior Court Division, Wake County, North Carolina (case number 16CV008930), on behalf of the Company against certain of our current officers and directors. The complaint alleges, among other things, that the defendants breached their fiduciary duties by disseminating false and misleading information to the Company’s shareholders relating to the Company’s SurgiBot System and its 510(k) application in violation of certain federal securities laws and by failing to ensure that the Company maintained adequate internal controls. The complaint seeks, among other things, unspecified monetary damages and an order directing the Company to take steps to improve its corporate governance and to protect the Company and its stockholders from future wrongdoing such as that alleged in the complaint. On September 29, 2016, the court entered an order staying the litigation pending resolution of the motion to dismiss the Amended Complaint in the Bankley Action. On April 25, 2016, Intuitive Surgical, Inc. and its French subsidiary, Intuitive Surgical SAS (collectively, “Intuitive”), brought a request for unilateral measures of enquiry in front of the President of the Commercial Court of Toulon (France) (the “President”) against two employees of TransEnterix International, Inc. alleging that the company, through these two employees, engaged in acts of unfair competition. On May 3, 2016, the President rendered an order granting Intuitive’s request for unilateral measures of enquiry with respect to its allegations (the “Order”). On June 28, 2016, TransEnterix International filed a writ challenging the Order and requesting that it be withdrawn by the President. On September 7, 2016, the President rendered his decision on TransEnterix International’s challenge (the “Ruling”) and ruled in favor of TransEnterix International. Under the Ruling, the Intuitive unilateral measures of enquiry were declared to be unjustified and the Order was withdrawn. The President also declared that the Ruling was provisionally enforceable. Intuitive has filed an appeal against the Ruling (the “Appeal”) with the Court of Appeal of Aix-en-Provence (France). No hearing date for the Appeal has yet been noticed. In addition, because Intuitive did not comply with the Ruling, TransEnterix International filed a dismissal request against the Appeal with the same Court of Appeal (the “Dismissal Request”). A hearing has been scheduled on January 3, 2017 with respect to the Dismissal Request.

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Basis of Presentation

Going Concern

Use of Estimates

Cash and Cash Equivalents and Restricted Cash

Fair Value of Financial Instruments

Concentrations and Credit Risk

Accounts Receivable

Inventories

Identifiable Intangible Assets and Goodwill

In-Process Research and Development

Property and Equipment

Property and equipment consists primarily of machinery, manufacturing equipment, computer equipment, furniture, and leasehold improvements, which are recorded at cost.

Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:

Machinery and manufacturing equipment		3-5 years
Computer equipment		3 years
Furniture		5 years
Leasehold improvements		Lesser of lease term or 3 to 10 years

Impairment of Long-Lived Assets

Contingent Consideration

Translation of Foreign Currencies

Business Acquisitions

Risk and Uncertainties

Revenue Recognition

•Instruments and accessories. Revenue from sales of instruments and accessories is generally recognized at the time of shipment.

Research and Development Costs

Stock-Based Compensation

Income Taxes

Comprehensive Loss

Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.

Segments

Impact of Recently Issued Accounting Standards

2. Summary of Significant Accounting Policies (Continued)

Reclassifications

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Summary of Estimated Lives of Assets

Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:

Machinery and manufacturing equipment		3-5 years
Computer equipment		3 years
Furniture		5 years
Leasehold improvements		Lesser of lease term or 3 to 10 years

Acquisition of Senhance Surgical Robotic System (Tables) - Senhance Surgical Robotic System Acquisition [Member]

9 Months Ended

Sep. 30, 2016

Summary of Fair Value Consideration

The Senhance Acquisition-date fair value of the consideration is as follows (in thousands, except for per share amounts):

Common shares issued		15,543
Closing price per share	$	2.81
	$	43,677
Cash consideration		25,000
Contingent consideration		23,900
Total consideration	$	92,577

Schedule of Estimated Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed on September 21, 2015, the date of acquisition (in thousands):

Accounts receivable	$	78
Inventories		2,800
Current deferred tax asset		526
Other current assets		4,180
Property and equipment		1,384
Intellectual property		48,500
In-process research and development		17,100
Goodwill		38,348
Total assets acquired	$	112,916
Accounts payable and other liabilities		1,915
Long-term deferred tax liabilities		18,424
Net assets acquired	$	92,577

Cash, Cash Equivalents and Restricted Cash (Tables)

9 Months Ended

Sep. 30, 2016

Cash And Cash Equivalents [Abstract]

Summary of Cash, Cash Equivalents and Restricted Cash

Cash, cash equivalents and restricted cash consist of the following:

	September 30,		December 31,
	2016		2015
	(In thousands)
	(unaudited)
Cash	$	2,366	$	1,666
Money market		40,152		36,783
Total cash and cash equivalents	$	42,518	$	38,449
Restricted cash	$	10,353	$	—
Total	$	52,871	$	38,449

Fair Value (Tables)

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Summary of Assets Measured at Fair Value on Recurring Basis

	September 30, 2016
	(In thousands)
	(unaudited)
Description	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets measured at fair value
Cash and cash equivalents	$	42,518	$	—	$	—	$	42,518
Restricted cash		10,353		—		—		10,353
Total Assets measured at fair value	$	52,871	$	—	$	—	$	52,871
Liabilities measured at fair value
Contingent consideration	$	—	$	—	$	25,200	$	25,200
Total liabilities measured at fair value	$	—	$	—	$	25,200	$	25,200

	December 31, 2015
	(In thousands)
Description	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets measured at fair value
Cash and cash equivalents	$	38,449	$	—	$	—	$	38,449
Total Assets measured at fair value	$	38,449	$	—	$	—	$	38,449
Liabilities measured at fair value
Contingent consideration	$	—	$	—	$	23,500	$	23,500
Total liabilities measured at fair value	$	—	$	—	$	23,500	$	23,500

Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classified in Level 3

Valuation

Methodology

Significant

Unobservable Input

Weighted Average

(range, if

applicable)

Contingent consideration

Probability weighted

income approach

Milestone dates

2016 to 2017

Discount rate

Probability of occurrence

7.5% to 9.0%

100%

Change in Fair Value for All Assets and Liabilities Using Unobservable Level 3 Inputs As Determined By Level 3 Inputs

	Fair Value Measurement at Reporting Date (Level 3)
	(In thousands)
	(unaudited)
Balance at December 31, 2015	$	23,500
Change in fair value		1,700
Balance at September 30, 2016	$	25,200
Current portion		11,325
Long-term portion		13,875
Balance at September 30, 2016	$	25,200

Accounts Receivable, Net (Tables)

9 Months Ended

Sep. 30, 2016

Receivables [Abstract]

Summary of Accounts Receivable

The following table presents the components of accounts receivable:

	September 30,			December 31,
	2016			2015
	(In thousands)
	(unaudited)
Gross accounts receivable	$	968		$	76
Allowance for uncollectible accounts		(78	)		—
Total accounts receivable, net	$	890		$	76
Short-term portion	$	616		$	76
Long-term portion		274			—
Total accounts receivable	$	890		$	76

Inventories (Tables)

9 Months Ended

Sep. 30, 2016

Inventory Disclosure [Abstract]

Schedule of Inventory

The components of inventories are as follows:

	September 30,		December 31,
	2016		2015
	(In thousands)
	(unaudited)
Finished goods	$	2,250	$	2,704
Raw materials		—		1,928
Total inventories	$	2,250	$	4,632
Short-term portion	$	2,250	$	3,923
Long-term portion		—		709
Total inventories	$	2,250	$	4,632

Other Current Assets (Tables)

9 Months Ended

Sep. 30, 2016

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Schedule of Other Current Assets

The following table presents the components of other current assets:

	September 30,		December 31,
	2016		2015
	(In thousands)
	(unaudited)
Advances to vendors	$	5,714	$	5,403
Prepaid expenses		2,060		750
Other receivables		375		536
Total	$	8,149	$	6,689

Property and Equipment (Tables)

9 Months Ended

Sep. 30, 2016

Property Plant And Equipment [Abstract]

Summary of Property and Equipment

Property and equipment consisted of the following:

	September 30,			December 31,
	2016			2015
	(In thousands)
	(unaudited)
Machinery and manufacturing equipment	$	6,357		$	5,846
Computer equipment		2,052			1,875
Furniture		448			374
Leasehold improvements		1,898			1,700
Total property and equipment		10,755			9,795
Accumulated depreciation and amortization		(6,141	)		(5,387	)
Property and equipment, net	$	4,614		$	4,408

Goodwill, In-Process Research and Development and Intellectual Property (Tables)

9 Months Ended

Sep. 30, 2016

Carrying Value of Goodwill and Change in Balance

The carrying value of goodwill and the change in the balance for the nine months ended September 30, 2016 is as follows:

	Goodwill
	(In thousands)
	(unaudited)
Balance at December 31, 2015	$	130,869
Foreign currency translation impact		863
Impairment loss		(61,784	)
Balance at September 30, 2016	$	69,948

Carrying Value of Company's Intangible Assets and Change in Balance

The components of gross intellectual property, accumulated amortization, and net intellectual property as of September 30, 2016 and December 31, 2015 are as follows:

	September 30, 2016													December 31, 2015
	(In thousands)													(In thousands)
	Gross Carrying Amount		Accumulated Amortization			Foreign currency translation impact			Write-off			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Foreign currency translation impact			Net Carrying Amount
Patents	$	5,000	$	(3,438	)	$	—		$	(1,562	)	$	—	$	5,000	$	(3,259	)	$	—		$	1,741
Developed technology		48,500		(6,803	)		(437	)		—			41,260		48,500		(1,672	)		(1,671	)		45,157
Total intellectual property	$	53,500	$	(10,241	)	$	(437	)	$	(1,562	)	$	41,260	$	53,500	$	(4,931	)	$	(1,671	)	$	46,898

In-Process Research and Development [Member]

Carrying Value of Company's Intangible Assets and Change in Balance

The carrying value of the Company’s IPR&D assets and the change in the balance for the nine months ended September 30, 2016 is as follows:

	In-Process Research and Development (In thousands)
	(unaudited)
Balance at December 31, 2015	$	16,511
Foreign currency translation impact		461
Balance at September 30, 2016	$	16,972

Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2016

Accrued Liabilities Current [Abstract]

Schedule of Accrued Expenses

The following table presents the components of accrued expenses:

	September 30,		December 31,
	2016		2015
	(In thousands)
	(unaudited)
Taxes and other assessments	$	3,220	$	3,112
Compensation and benefits		1,718		2,492
Interest and final payment fee		881		411
Deferred rent		301		278
Consulting and other vendors		776		553
Legal and professional fees		226		268
Restructuring charges		49		—
Other		75		281
Total	$	7,246	$	7,395

Public Offerings of Common Stock (Tables)

9 Months Ended

Sep. 30, 2016

Text Block [Abstract]

Schedule of Total Sales under 2015 and 2016 Sales Agreement

The following table summarizes the total sales under the 2015 Sales Agreement and 2016 Sales Agreement for the periods indicated (in thousands, except per share amounts):

	2015 Sales Agreement				2016 Sales Agreement
	Nine Months Ended September 30, 2016		Year Ended December 31, 2015		Nine Months Ended September 30, 2016
Total shares of common stock sold		5,710.2		2,014.3		8,763.4
Average price per share	$	3.23	$	3.25	$	4.70
Gross proceeds	$	18,454	$	6,546	$	41,156
Commissions earned by Cantor	$	553	$	197	$	1,235
Other issuance costs	$	—	$	259	$	185

Organization and Capitalization - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2016 Segment shares	Dec. 31, 2015 shares	Dec. 06, 2013 $ / shares shares
Organization and Capitalization [Line Items]
Common stock, shares authorized	750,000,000	750,000,000
Preferred stock, shares authorized			25,000,000
Preferred stock, par value (in dollars per share) \| $ / shares			$ 0.01
Number of business segments \| Segment	1
Minimum [Member]
Organization and Capitalization [Line Items]
Common stock, shares authorized			225,000,000
Maximum [Member]
Organization and Capitalization [Line Items]
Common stock, shares authorized			750,000,000

Summary of Significant Accounting Policies - Additional Information (Detail)		9 Months Ended		12 Months Ended
	Sep. 21, 2015	Sep. 30, 2016 USD ($) Segment	Sep. 30, 2015 USD ($)	Dec. 31, 2015 USD ($)
Accounting Policies [Line Items]
Accumulated deficit		$ (288,852,000)		$ (182,864,000)
Restricted cash		10,353,000
Impairment charges		$ 0		0
Period of free service sale arrangement		1 year
Number of business segments \| Segment		1
Goodwill		$ 197,032,000		$ 248,602,000
U.S. [Member]
Accounting Policies [Line Items]
Percentage of total consolidated assets		53.00%
International [Member]
Accounting Policies [Line Items]
Percentage of total consolidated assets, excluding goodwill		37.00%
Senhance Surgical Robotic System Acquisition [Member]
Accounting Policies [Line Items]
Amortization period	7 years
Senhance Surgical Robotic System Acquisition [Member] \| Europe [Member]
Accounting Policies [Line Items]
Goodwill		$ 93,300,000
Stock Options [Member]
Accounting Policies [Line Items]
Share based compensation, expense recognized		$ 3,858,000	$ 2,388,000
Minimum [Member]
Accounting Policies [Line Items]
Amortization period		7 years
Maximum [Member]
Accounting Policies [Line Items]
Amortization period		10 years
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer One [Member]
Accounting Policies [Line Items]
Concentration Risk Percentage		100.00%		100.00%
Held In Cash Money Market Account [Member]
Accounting Policies [Line Items]
Restricted cash		$ 10,000,000
Held In Cash Collateral Accounts [Member]
Accounting Policies [Line Items]
Restricted cash		$ 353,000

Summary of Significant Accounting Policies - Summary of Estimated Lives of Assets (Detail)	9 Months Ended
	Sep. 30, 2016
Computer Equipment [Member]
Change In Accounting Estimate [Line Items]
Property, plant and equipment, useful life	3 years
Furniture [Member]
Change In Accounting Estimate [Line Items]
Property, plant and equipment, useful life	5 years
Minimum [Member] \| Machinery and Manufacturing Equipment [Member]
Change In Accounting Estimate [Line Items]
Property, plant and equipment, useful life	3 years
Minimum [Member] \| Leasehold Improvements [Member]
Change In Accounting Estimate [Line Items]
Property, plant and equipment, useful life	3 years
Maximum [Member] \| Machinery and Manufacturing Equipment [Member]
Change In Accounting Estimate [Line Items]
Property, plant and equipment, useful life	5 years
Maximum [Member] \| Leasehold Improvements [Member]
Change In Accounting Estimate [Line Items]
Property, plant and equipment, useful life	10 years

Acquisition of Senhance Surgical Robotic System - Additional Information (Detail)			3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 21, 2016	Sep. 21, 2015 USD ($) shares	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Dec. 31, 2015 USD ($)	Sep. 21, 2015 EUR (€)
Business Acquisition [Line Items]
Securities consideration held in escrow percentage		10.00%
Escrow and security interest period		24 months
Intellectual property, net				$ 41,260,000		$ 46,898,000
Legal, consulting and other costs related to acquisition			$ 4,003,000		$ 4,003,000
Minimum [Member]
Business Acquisition [Line Items]
Amortization period				7 years
Senhance Surgical Robotic System Acquisition [Member]
Business Acquisition [Line Items]
Common shares issued \| shares		15,543,413
Cash consideration		$ 25,000,000
Percentage of securities consideration released from lock out restrictions	50.00%
Percentage of securities consideration	50.00%
Acquisition agreement, description				The Lock-up Agreement provides that an additional twenty-five percent of the Securities Consideration remains locked-up until the eighteen-month anniversary of the Closing Date, and the remaining twenty-five percent of the Securities Consideration remains locked-up until the two-year anniversary of the Closing Date.
Intellectual property, net		$ 48,500,000
Amortization period		7 years
Senhance Surgical Robotic System Acquisition [Member] \| Ending on Eighteen Month Anniversary [Member]
Business Acquisition [Line Items]
Percentage of securities consideration	25.00%
Senhance Surgical Robotic System Acquisition [Member] \| Ending on Two Year Anniversary [Member]
Business Acquisition [Line Items]
Percentage of securities consideration	25.00%
Senhance Surgical Robotic System Acquisition [Member] \| First Tranche [Member]
Business Acquisition [Line Items]
Cash consideration		$ 25,000,000
Senhance Surgical Robotic System Acquisition [Member] \| Second Tranche [Member]
Business Acquisition [Line Items]
Cash consideration payable \| €							€ 10,000,000
Gross proceeds from financing		$ 50,000,000
Interest rate		9.00%					9.00%
Senhance Surgical Robotic System Acquisition [Member] \| Second Tranche [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Cash on hand		$ 50,000,000
Senhance Surgical Robotic System Acquisition [Member] \| Third Tranche [Member]
Business Acquisition [Line Items]
Cash consideration payable \| €							€ 15,000,000
Senhance Surgical Robotic System Acquisition [Member] \| Third Tranche [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Target revenue to be achieved \| €							25,000,000
Senhance Surgical Robotic System Acquisition [Member] \| Fourth Tranche [Member]
Business Acquisition [Line Items]
Cash consideration payable \| €							2,500,000
Senhance Surgical Robotic System Acquisition [Member] \| U.S. Dollars [Member]
Business Acquisition [Line Items]
Cash consideration		$ 25,000,000
Senhance Surgical Robotic System Acquisition [Member] \| Euro [Member]
Business Acquisition [Line Items]
Cash consideration payable \| €							€ 27,500,000
TransEnterix Italia [Member]
Business Acquisition [Line Items]
Membership interests percentage under Security agreement		10.00%					10.00%
Legal, consulting and other costs related to acquisition						$ 4,200,000

Acquisition of Senhance Surgical Robotic System - Summary of Fair Value Consideration (Detail) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended	12 Months Ended
	Sep. 21, 2015	Sep. 30, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Contingent consideration		$ 25,200	$ 23,500
Senhance Surgical Robotic System Acquisition [Member]
Business Acquisition [Line Items]
Common shares issued	15,543,413
Closing price per share	$ 2.81
Consideration share value	$ 43,677
Cash consideration	25,000
Contingent consideration	23,900	$ 25,200
Total consideration	$ 92,577

Acquisition of Senhance Surgical Robotic System - Schedule of Estimated Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015	Sep. 21, 2015
Business Acquisition [Line Items]
Goodwill	$ 69,948	$ 130,869
Senhance Surgical Robotic System Acquisition [Member]
Business Acquisition [Line Items]
Accounts receivable			$ 78
Inventories			2,800
Current deferred tax asset			526
Other current assets			4,180
Property and equipment			1,384
Intellectual property			48,500
In-process research and development			17,100
Goodwill	$ 38,300		38,348
Total assets acquired			112,916
Accounts payable and other liabilities			1,915
Long-term deferred tax liabilities			18,424
Net assets acquired			$ 92,577

Cash, Cash Equivalents and Restricted Cash - Summary of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Cash And Cash Equivalents [Abstract]
Cash	$ 2,366	$ 1,666
Money market	40,152	36,783
Total cash and cash equivalents	42,518	38,449	$ 52,893	$ 34,766
Restricted cash	10,353
Total	$ 52,871	$ 38,449

Fair Value - Summary of Assets Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Assets measured at fair value
Cash and cash equivalents	$ 42,518	$ 38,449	$ 52,893	$ 34,766
Restricted cash	10,353
Total	52,871	38,449
Liabilities measured at fair value
Contingent consideration	25,200	23,500
Total liabilities measured at fair value	25,200	23,500
Fair Value, Inputs, Level 1 [Member]
Assets measured at fair value
Cash and cash equivalents	42,518	38,449
Restricted cash	10,353
Total	52,871	38,449
Fair Value, Inputs, Level 3 [Member]
Liabilities measured at fair value
Contingent consideration	25,200	23,500
Total liabilities measured at fair value	$ 25,200	$ 23,500

Fair Value - Additional Information (Detail) - USD ($)	9 Months Ended
Fair Value - Additional Information (Detail) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Fair Value Measurements Disclosure [Line Items]
Fair value of contingent consideration		$ 24,300,000
Senhance Surgical Robotic System Acquisition [Member]
Fair Value Measurements Disclosure [Line Items]
Fair value of contingent consideration	$ 1,700,000

Fair Value - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classified in Level 3 (Detail) - Senhance Surgical Robotic System Acquisition [Member] - Fair Value, Inputs, Level 3 [Member] - Contingent Consideration [Member]	9 Months Ended
	Sep. 30, 2016
Fair Value Inputs Liabilities Quantitative Information [Line Items]
Probability of occurrence	100.00%
Minimum [Member]
Fair Value Inputs Liabilities Quantitative Information [Line Items]
Milestone dates	2016
Discount rate	7.50%
Maximum [Member]
Fair Value Inputs Liabilities Quantitative Information [Line Items]
Milestone dates	2017
Discount rate	9.00%

Fair Value - Change in Fair Value for All Assets and Liabilities Using Unobservable Level 3 Inputs As Determined By Level 3 Inputs (Detail) - Fair Value, Inputs, Level 3 [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 23,500
Change in fair value	1,700
Current portion	11,325
Long-term portion	13,875
Ending balance	$ 25,200

Accounts Receivable, Net - Summary of Accounts Receivable (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Receivables [Abstract]
Gross accounts receivable	$ 968	$ 76
Allowance for uncollectible accounts	(78)
Total accounts receivable, net	890	76
Short-term portion	616	$ 76
Long-term portion	$ 274

Inventories - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Finished goods	$ 2,250	$ 2,704
Raw materials		1,928
Total inventories	2,250	4,632
Short-term portion	$ 2,250	3,923
Long-term portion		$ 709

Inventories - Additional Information (Detail) - USD ($)	9 Months Ended
Inventories - Additional Information (Detail) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Inventory [Line Items]
Write down of inventory	$ 2,565,000
SurgiBot System [Member]
Inventory [Line Items]
Write down of inventory	$ 2,600,000	$ 0

Other Current Assets - Schedule of Other Current Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Advances to vendors	$ 5,714	$ 5,403
Prepaid expenses	2,060	750
Other receivables	375	536
Total	$ 8,149	$ 6,689

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	$ 10,755	$ 9,795
Accumulated depreciation and amortization	(6,141)	(5,387)
Property and equipment, net	4,614	4,408
Machinery and Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	6,357	5,846
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	2,052	1,875
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	448	374
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	$ 1,898	$ 1,700

Property and Equipment - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Property Plant And Equipment [Abstract]
Disposal of long-lived assets	$ 1,000,000	$ 0
Depreciation	$ 1,498,000	$ 802,000

Goodwill, In-Process Research and Development and Intangible Assets - Additional Information (Detail) - USD ($)		3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 21, 2015	Jun. 30, 2016	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2009
Goodwill And Intangible Assets [Line Items]
Goodwill			$ 69,948,000		$ 130,869,000
Goodwill impairment		$ 61,800,000	61,784,000		0
In-process research and development			16,972,000		16,511,000
Patent purchased amount			53,500,000		53,500,000
Write-off of intellectual property			1,562,000
In-Process Research and Development [Member]
Goodwill And Intangible Assets [Line Items]
In-process research and development			16,972,000		16,511,000
Discount rate	45.00%
Patents [Member]
Goodwill And Intangible Assets [Line Items]
Patent purchased amount			5,000,000		$ 5,000,000	$ 5,000,000
Write-off of intellectual property			1,562,000
Patents [Member] \| SurgiBot System [Member]
Goodwill And Intangible Assets [Line Items]
Write-off of intellectual property			1,600,000	$ 0
Intellectual Property [Member]
Goodwill And Intangible Assets [Line Items]
Discount rate	45.00%
Safe Stitch Medical Inc [Member]
Goodwill And Intangible Assets [Line Items]
Goodwill			93,800,000
Senhance Surgical Robotic System Acquisition [Member]
Goodwill And Intangible Assets [Line Items]
Goodwill	$ 38,348,000		$ 38,300,000
Intellectual property	48,500,000
Senhance Surgical Robotic System Acquisition [Member] \| In-Process Research and Development [Member]
Goodwill And Intangible Assets [Line Items]
In-process research and development	$ 17,100,000

Goodwill, In-Process Research and Development and Intangible Assets - Carrying Value of Goodwill and Change in Balance (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2016	Sep. 30, 2016	Dec. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Beginning balance		$ 130,869
Foreign currency translation impact		863
Impairment loss	$ (61,800)	(61,784)	$ 0
Ending balance		$ 69,948	$ 130,869

Goodwill, In-Process Research and Development and Intangible Assets - Carrying Value of Company's IPR&D Assets and Change in Balance (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Beginning balance	$ 16,511
Foreign currency translation impact	(437)	$ (1,671)
Ending balance	16,972	16,511
In-Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Beginning balance	16,511
Foreign currency translation impact	461
Ending balance	$ 16,972	$ 16,511

Goodwill, In-Process Research and Development and Intellectual Property - Summary of Gross Intellectual Property, Accumulated Amortization, and Net Intellectual Property (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2009
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 53,500	$ 53,500
Accumulated Amortization	(10,241)	(4,931)
Foreign currency translation impact	(437)	(1,671)
Write-off	(1,562)
Net Carrying Amount	41,260	46,898
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	5,000	5,000	$ 5,000
Accumulated Amortization	(3,438)	(3,259)
Write-off	(1,562)
Net Carrying Amount		1,741
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	48,500	48,500
Accumulated Amortization	(6,803)	(1,672)
Foreign currency translation impact	(437)	(1,671)
Net Carrying Amount	$ 41,260	$ 45,157

Income Taxes - Additional Information (Detail) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016
Income Tax Contingency [Line Items]
Deferred tax benefit	$ 4,700,000
Effective tax rate	4.30%	0.00%
Unrecognized tax benefits	$ 0
Scenario, Forecast [Member]
Income Tax Contingency [Line Items]
Estimated annual effective tax rate			5.10%
TransEnterix Italia [Member]
Income Tax Contingency [Line Items]
Adjustment to deferred tax liability	$ 1,700,000

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Accrued Liabilities Current [Abstract]
Taxes and other assessments	$ 3,220	$ 3,112
Compensation and benefits	1,718	2,492
Interest and final payment fee	881	411
Deferred rent	301	278
Consulting and other vendors	776	553
Legal and professional fees	226	268
Restructuring charges	49
Other	75	281
Total	$ 7,246	$ 7,395

Notes Payable - Additional Information (Detail) - USD ($)					9 Months Ended
	Sep. 18, 2015	Aug. 14, 2015	Sep. 26, 2014	Jan. 17, 2012	Sep. 30, 2016	Sep. 07, 2016	Apr. 19, 2016
Debt Instrument [Line Items]
Debt discount liability, facility fee			$ 75,000
Warrant expiration period			7 years
Cash balance in accounts held with the lender					$ 10,353,000
Approximated Amount of debt discount			$ 129,000
Fair value of warrants on the issue date			54,000
Debt discount liability, legal fees			30,000
Amended and Restated Term Loans [Member]
Debt Instrument [Line Items]
Term loan aggregate principal amount			$ 25,000,000
Interest only payment percentage			7.50%
Maturity date of the term loans			Apr. 01, 2018
Debt instrument, redemption price percentage					5.45%
Debt Instrument, redemption price amount					$ 165,920
Debt discount liability, facility fee					$ 90,000
Issue of warrants to purchase shares of company's common stock					38,324
Percentage of common stock pledged					100.00%
Amended and Restated Term Loans [Member] \| First Tranche [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Amount of borrowing under agreement			$ 5,604,000
Amended and Restated Term Loans [Member] \| First Tranche [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Amount of borrowing under agreement			10,000,000
First Amended and Restated Loan Agreement [Member]
Debt Instrument [Line Items]
Interest only payment percentage		7.50%
Maturity date of the term loans		Oct. 01, 2018
Debt discount liability, facility fee					$ 90,000
Issue of warrants to purchase shares of company's common stock					112,903
First Amended and Restated Loan Agreement [Member] \| First Tranche [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Amount of borrowing under agreement		$ 10,000,000
First Amended and Restated Loan Agreement [Member] \| First Tranche [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Amount of borrowing under agreement		$ 20,000,000
Second Amended and Restated Loan Agreement [Member]
Debt Instrument [Line Items]
Interest only payment percentage	7.50%
Maturity date of the term loans	Jul. 01, 2018
Second Amended and Restated Loan Agreement [Member] \| Without Interest- Only Extension [Member]
Debt Instrument [Line Items]
Debt instrument, redemption price percentage					6.50%
Second Amended and Restated Loan Agreement [Member] \| With Interest-Only Extension [Member]
Debt Instrument [Line Items]
Debt instrument, redemption price percentage					8.00%
Fourth Amended and Restated Loan Agreement [Member] \| Maximum [Member] \| TransEnterix Europe [Member]
Debt Instrument [Line Items]
Percentage of equity interest owned							65.00%
Fifth Amended and Restated Loan Agreement [Member]
Debt Instrument [Line Items]
Cash balance in accounts held with the lender						$ 10,000,000
Notes Payable [Member]
Debt Instrument [Line Items]
Debt discount liability, discount					$ 210,000
Debt issuance costs paid to lenders and third parties					371,000
Debt issuance cost					280,000
Debt unamortized balance					$ 143,000
Loan and Security Agreement [Member]
Debt Instrument [Line Items]
Note issuance date				Jan. 17, 2012
Issuance of promissory note as part of merger transaction				$ 10,000,000
Maturity date				Jan. 01, 2016
Term loan fixed interest rate				8.75%
Outstanding principal amount of the original loan agreement			$ 5,604,000
Debt instrument, redemption price percentage			3.33%
Debt Instrument, redemption price amount			$ 333,000
Debt discount liability, facility fee			$ 75,000
Issue of warrants to purchase shares of company's common stock				279,588
Loan and Security Agreement [Member] \| Term A Loan [Member]
Debt Instrument [Line Items]
Issuance of promissory note as part of merger transaction				$ 4,000,000
Loan and Security Agreement [Member] \| Term B Loan [Member]
Debt Instrument [Line Items]
Issuance of promissory note as part of merger transaction				$ 6,000,000

Restructuring - Additional Information (Detail) - USD ($)	1 Months Ended	9 Months Ended
	May 31, 2016	Sep. 30, 2016	Sep. 30, 2015
Restructuring Cost And Reserve [Line Items]
Inventory write-down related to restructuring		$ 2,565,000
Restructuring and other charges		3,085,000
Restructuring and other charges related to other non-cash charges		2,551,000
Disposal of long-lived assets		1,000,000	$ 0
Write-off of intellectual property		1,562,000
Patents [Member]
Restructuring Cost And Reserve [Line Items]
Write-off of intellectual property		1,562,000
SurgiBot System [Member]
Restructuring Cost And Reserve [Line Items]
Inventory write-down related to restructuring		2,600,000	0
SurgiBot System [Member] \| Patents [Member]
Restructuring Cost And Reserve [Line Items]
Write-off of intellectual property		1,600,000	$ 0
Headcount, Discontinued Efforts and Cancellation of Contracts [Member] \| SurgiBot System [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring charges	$ 5,700,000
Inventory write-down related to restructuring	2,600,000
Restructuring and other charges	3,100,000
Restructuring amount paid in cash	500,000
Employee severance costs	400,000
Restructuring and other charges related to cancellation of contracts	100,000
Restructuring and other charges related to other non-cash charges	2,600,000
Disposal of long-lived assets	1,000,000
Headcount, Discontinued Efforts and Cancellation of Contracts [Member] \| SurgiBot System [Member] \| Accrued Expenses [Member]
Restructuring Cost And Reserve [Line Items]
Total future payments under plan		$ 49,000
Headcount, Discontinued Efforts and Cancellation of Contracts [Member] \| SurgiBot System [Member] \| Patents [Member]
Restructuring Cost And Reserve [Line Items]
Write-off of intellectual property	$ 1,600,000

Public Offerings of Common Stock - Additional Information (Detail) - USD ($)						9 Months Ended
	Feb. 09, 2016	Jul. 10, 2015	Jun. 11, 2015	Feb. 20, 2015	Apr. 30, 2014	Sep. 30, 2016	Sep. 30, 2015	Mar. 03, 2016	Mar. 02, 2016	Dec. 31, 2015	Apr. 14, 2014
Stockholders Equity Common Stock [Line Items]
Total shares of common stock sold						115,086,256				100,180,872
Net Proceeds		$ 5,800,000	$ 46,400,000		$ 52,400,000	$ 57,637,000	$ 58,295,000
Common stock to be sold, shares			16,666,667								12,500,000
Public offering price		$ 3.00	$ 3.00		$ 4.00						$ 4.00
Expected aggregate gross proceeds			$ 50,000,000								$ 50,000,000
Over-allotment option, shares to be issued to underwriters			2,500,000								1,875,000
Shares issued from option exercise by underwriters		2,075,000			1,610,000
Additional proceeds from exercise of option by underwriters		$ 6,200,000			$ 6,400,000
Proceeds from issuance of common stock from public offering, net of issuance costs						52,200,000
Issuance costs of Issuance of common shares					4,000,000	4,000,000
Aggregate maximum value of designated securities to be sold					$ 100,000,000	100,000,000		$ 150,000,000	$ 100,000,000
Value of stock to be purchased by existing stockholders											$ 10,000,000
Amount available for future financing of common stock						$ 71,200,000
Cantor Fitzgerald & Co. [Member]
Stockholders Equity Common Stock [Line Items]
Sale of common stock in an at-the-market offering	43,600,000			25,000,000
Percentage of commission paid	3.00%			3.00%
Total shares of common stock sold	7,724,488
Gross proceeds	$ 25,000,000
Net Proceeds	$ 24,000,000

Public Offerings of Common Stock - Schedule of Total Sales under 2015 and 2016 Sales Agreement (Detail) - Cantor Fitzgerald & Co. [Member] - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended	12 Months Ended
	Feb. 09, 2016	Sep. 30, 2016	Dec. 31, 2015
Sale And Issue Of Shares Under Agreement [Line Items]
Gross proceeds	$ 25,000
2015 Sales Agreement [Member]
Sale And Issue Of Shares Under Agreement [Line Items]
Total shares of common stock sold		5,710,200	2,014,300
Average price per share		$ 3.23	$ 3.25
Gross proceeds		$ 18,454	$ 6,546
Commissions earned by Cantor		$ 553	197
Other issuance costs			$ 259
2016 Sales Agreement [Member]
Sale And Issue Of Shares Under Agreement [Line Items]
Total shares of common stock sold		8,763,400
Average price per share		$ 4.70
Gross proceeds		$ 41,156
Commissions earned by Cantor		1,235
Other issuance costs		$ 185

Related Person Transactions - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Synecor, LLC [Member]
Related Party Transaction [Line Items]
Payments to Acquire in Process Research and Development	$ 5,000	$ 434,000
Officer [Member] \| Synergy Life Science Partners, L.P. and Synecor, LLC [Member] \| Common Stock [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	5.00%	6.00%
SOFAR [Member]
Related Party Transaction [Line Items]
Expenses under service agreement with related party	$ 162,000	$ 0
SOFAR [Member] \| Common Stock [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	13.50%	15.50%

Commitments and Contingencies - Additional Information (Detail) $ in Thousands		9 Months Ended	12 Months Ended
	Sep. 21, 2015 USD ($)	Sep. 30, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2016 EUR (€)
Operating Leased Assets [Line Items]
Fair value of contingent consideration		$ 25,200	$ 23,500
Senhance Surgical Robotic System Acquisition [Member]
Operating Leased Assets [Line Items]
Fair value of contingent consideration	$ 23,900	$ 25,200
Senhance Surgical Robotic System Acquisition [Member] \| Maximum [Member]
Operating Leased Assets [Line Items]
Aggregate milestone payments \| €				€ 27,500,000